Week of December 10, 2012: Amgen Agrees to Acquire deCODE Genetics; Baxter International Agrees to Acquire Gambro; and More - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Week of December 10, 2012: Amgen Agrees to Acquire deCODE Genetics; Baxter International Agrees to Acquire Gambro; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Amgen has agreed to acquire the Reykjavik, Iceland-based, human-genetics R&D company deCODE Genetics. The all-cash transaction values deCODE Genetics at $415 million, subject to customary closing adjustments, and was unanimously approved by Amgen’s board of directors. Read More

Baxter International has agreed to acquire Gambro, a privately held dialysis-product company based in Lund, Sweden, for total consideration of SEK 26.5 billion (USD 4 billion). The transaction will be financed through a combination of cash generated from overseas operations and debt. Baxter expects to maintain its current dividend payout ratio of approximately 40%. The closing of the transaction is subject to regulatory approvals and other customary closing conditions and is expected to occur in the first half of 2013. Read More

Following a five-year partnership with Exelixis during which Catalent Pharma Solutions has provided analytical, clinical-trial supply, and manufacturing support for Cometriq (cabozantinib), FDA has approved Exelixis’ aforementioned treatment of progressive, metastatic medullary thyroid cancer. Catalent will now continue to be the exclusive commercial drug-supply partner for the 20- and 80-mg capsule dose packs in the US. All US Cometriq capsule manufacturing and packaging operations will be undertaken at Catalent’s 450,000-ft2 facility in Kansas City, Missouri. Read More

The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer. Under the agreement, MD Anderson grants GSK exclusive worldwide rights to develop and commercialize the antibodies, which activate OX40 (secondary receptor proteins) on the surface of T cells. MD Anderson, through its new Institute for Applied Cancer Science, will collaborate with GSK to conduct preclinical research on the antibodies. Read More

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here